Several studies confirmed that after inhibiting MDM2 expression, the expression of p53 and Bax can be up-regulated, while Bcl-2 expression can be down-regulated, resulting in increased drug sensitivity in tumor cells [37, 38]. The gene discussed is MDM2; the disease is neoplasm.